Clinical Trial Update: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase I trial evaluating a combination of Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab in indolent B-cell lymphomas has completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone B-cell Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• Vincristine sulfate liposome injection (vincristine sulfate liposome injection)

Snippet

Sponsor: Brown University | Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Follicular | Phase 1 | Status: COMPLETED | Results posted: 2023-02-09